Literature DB >> 26062395

CETSA: a target engagement assay with potential to transform drug discovery.

Annika Jenmalm Jensen1, Daniel Martinez Molina2, Thomas Lundbäck1.   

Abstract

Keywords:  CETSA; R&D efficiency; cellular thermal shift assay; phenotypic-based drug-discovery; target engagement; target-based drug-discovery

Mesh：

Substances：

Year:  2015        PMID： 26062395     DOI： 10.4155/fmc.15.50

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


× No keyword cloud information.
  13 in total

Review 1.  Applications of chemogenomic library screening in drug discovery.

Authors:  Lyn H Jones; Mark E Bunnage
Journal:  Nat Rev Drug Discov       Date:  2017-01-20       Impact factor: 84.694

2.  Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts.

Authors:  Katherine B Schuetze; Matthew S Stratton; Weston W Blakeslee; Michael F Wempe; Florence F Wagner; Edward B Holson; Yin-Ming Kuo; Andrew J Andrews; Tonya M Gilbert; Jacob M Hooker; Timothy A McKinsey
Journal:  J Pharmacol Exp Ther       Date:  2017-02-07       Impact factor: 4.030

3.  Photoaffinity Probe Reveals the Potential Target of Harringtonolide for Cancer Cell Migration Inhibition.

Authors:  Tian-Yu Zhu; Xiu-Tao Wu; Chen Chen; Xiao-Qin Liu; Li Zhu; Jian-Guang Luo; Ling-Yi Kong
Journal:  ACS Med Chem Lett       Date:  2022-02-02       Impact factor: 4.345

4.  The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.

Authors:  Abdulraheem Alshareef; Hai-Feng Zhang; Yung-Hsing Huang; Chengsheng Wu; Jing Dong Zhang; Peng Wang; Ahmed El-Sehemy; Mohamed Fares; Raymond Lai
Journal:  Sci Rep       Date:  2016-09-19       Impact factor: 4.379

5.  High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma.

Authors:  Abdulraheem Alshareef; Nidhi Gupta; Hai-Feng Zhang; Chengsheng Wu; Moinul Haque; Raymond Lai
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

Review 6.  Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.

Authors:  Abdulraheem Alshareef
Journal:  Cancers (Basel)       Date:  2017-10-28       Impact factor: 6.639

7.  Bavachinin exhibits antitumor activity against non‑small cell lung cancer by targeting PPARγ.

Authors:  Lu-Na Ge; Lei Yan; Cheng Li; Kai Cheng
Journal:  Mol Med Rep       Date:  2019-07-11       Impact factor: 3.423

Review 8.  Early Probe and Drug Discovery in Academia: A Minireview.

Authors:  Anuradha Roy
Journal:  High Throughput       Date:  2018-02-09

9.  3'-epi-12β-hydroxyfroside, a new cardenolide, induces cytoprotective autophagy via blocking the Hsp90/Akt/mTOR axis in lung cancer cells.

Authors:  Yan Sun; Yong-Hao Huang; Feng-Ying Huang; Wen-Li Mei; Quan Liu; Cai-Chun Wang; Ying-Ying Lin; Canhua Huang; Yue-Nan Li; Hao-Fu Dai; Guang-Hong Tan
Journal:  Theranostics       Date:  2018-02-15       Impact factor: 11.556

10.  Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.

Authors:  Brent D G Page; Nicholas C K Valerie; Roni H G Wright; Olov Wallner; Rebecka Isaksson; Megan Carter; Sean G Rudd; Olga Loseva; Ann-Sofie Jemth; Ingrid Almlöf; Jofre Font-Mateu; Sabin Llona-Minguez; Pawel Baranczewski; Fredrik Jeppsson; Evert Homan; Helena Almqvist; Hanna Axelsson; Shruti Regmi; Anna-Lena Gustavsson; Thomas Lundbäck; Martin Scobie; Kia Strömberg; Pål Stenmark; Miguel Beato; Thomas Helleday
Journal:  Nat Commun       Date:  2018-01-17       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.